Replies to post #8574 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The new guidance for operating cash burn excluding collaborative revenue from NVS (effectively reimbursement for MNTA’s R&D) and excluding MNTA’s small Lovenox royalty payable to MIT is $22-28M per quarter.

The above guidance includes an unspecified amount for MNTA’s portion of ongoing legal fees for the Lovenox patent case. (NVS pays 100% of the ongoing legal fees in the Copaxone patent case.)

[DewDiligence]

Tidbit from today’s MNTA CC: This was the first time Goldman Sachs was represented on a MNTA CC by Jami Rubin, the high-profile analyst who covers Big Pharma. Rubin sounded rather clueless when asking questions about the Copaxone ANDA, but her aggressive stance on the CC might be a prelude to stepped-up coverage of MNTA by GS.